Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )
16 Jun 2020
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neo...
Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )
13 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )
12 Jun 2020
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in...
Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )
12 Jun 2020
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurre...
Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany
AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )
12 Jun 2020
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based thera...
Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy
Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )
12 Jun 2020
ASCO 2020: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ASCO 2020: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
11 Jun 2020
COVID-19: Optimising supportive care during active cancer treatment
Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK
COVID-19: Optimising supportive care during active cancer treatment ( Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK )
10 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO 2020: Updates in renal cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
5 Jun 2020
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
2 Jun 2020